GLP-1 Consumer Protection
Your Compounded GLP-1 Program Is Ending: What to Do Now
Published June 2026 — Regulatory status reflects current FDA enforcement posture
The FDA has declared the national shortages of semaglutide and tirzepatide — the active ingredients in Ozempic, Wegovy, Mounjaro, and Zepbound — resolved. That declaration ended the legal basis for most compounded GLP-1 programs that millions of patients have been relying on for affordable access to these medications.
This guide explains what changed, what kind of program you're on, what it means for the major telehealth companies, what your legal rights are when a program ends, and how to evaluate every transition option available to you — ranked honestly.
What Changed — And Why
To understand why this is happening, you need to understand the legal mechanism that made compounded GLP-1 programs possible in the first place. It wasn't a loophole — it was a specific federal provision.
The Drug Shortage Exception
Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are generally prohibited from producing drugs that are "essentially a copy" of commercially available FDA-approved medications. The rationale is straightforward: if a drug is already manufactured and available, there is no clinical justification for compounders to produce unregulated versions of the same thing.
However, the law contains an important exception: when a drug is on the FDA's official drug shortage list, compounding pharmacies may produce versions of that drug to help address the supply gap. Strong
Beginning in 2022–2023, Ozempic, Wegovy, Mounjaro, and Zepbound all ended up on the FDA drug shortage list due to overwhelming demand outpacing manufacturing capacity. That shortage designation opened the door for compounding pharmacies to produce semaglutide and tirzepatide at scale — legally. The mass-market compounded GLP-1 industry grew directly from that window.
The Window Has Closed
The FDA has since declared the national shortages of both semaglutide and tirzepatide resolved. With that declaration, the legal basis for most compounded GLP-1 programs no longer exists. Strong
FDA enforcement has followed: the agency has escalated enforcement actions against telehealth companies and compounding pharmacies that continued mass-marketing compounded GLP-1s after shortage resolution, including referrals to the Department of Justice. State pharmacy boards — including California's — have updated their own regulations to restrict copycat compounding. Strong
Which Type of Program You're On: 503A vs. 503B
Not all compounding programs are the same, and the specific type of pharmacy behind your program determines exactly what is and isn't still legal. There are two categories:
| Type | What It Is | Current Status for GLP-1s | Still Legal? |
|---|---|---|---|
| 503A Pharmacy | Traditional state-licensed compounding pharmacy. Requires an individual patient prescription for each compound. Subject to state pharmacy board oversight. | Prohibited from producing drugs "essentially a copy" of commercially available medications outside an active shortage. Mass-produced programs are not permitted. Patient-specific formulations with documented clinical justification remain possible in limited cases. | Limited |
| 503B Outsourcing Facility | Large-scale, FDA-registered compounding facility. Can manufacture batches without individual patient prescriptions. Subject to FDA inspection and cGMP standards. | FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list entirely. Once that rule takes effect, mass-scale GLP-1 compounding by 503B facilities becomes illegal regardless of shortage status. | Ending |
What Kind of Program Are You On?
Most major telehealth GLP-1 programs — the kind advertised online for $99–$299/month — sourced their medication from 503B outsourcing facilities. These facilities provided the manufacturing scale needed to serve thousands of patients simultaneously. That supply chain is the one being shut down.
If you received your medication from a 503B-supplied telehealth program, the source of your supply is specifically targeted by the FDA's proposed bulks list exclusion. If your program used a 503A compounding pharmacy, your program was already operating in a legally fraught space after shortage resolution, and enforcement risk has increased significantly. Strong
What This Means for Major Telehealth GLP-1 Programs
The telehealth companies that built large-scale GLP-1 businesses on compounded medications face a fundamental business problem: the product they were selling at $99–$299/month is no longer legal to sell in that form. Their options are limited.
Option 1: Pivot to Brand-Name Prescribing
A telehealth company can transition to prescribing FDA-approved brand-name medications (Wegovy, Zepbound, Mounjaro, Ozempic) and help patients navigate insurance coverage, prior authorization, and manufacturer savings programs. This is a legitimate business model — it is essentially what traditional medical practices have always done.
The problem: brand-name GLP-1s cost $900–$1,400/month at retail. The savings cards that can bring that to near-zero require commercial insurance coverage. Many patients who chose compounded programs did so specifically because they lacked insurance coverage or their insurance would not cover GLP-1s for weight management. For these patients, brand-name prescribing is not a real substitute at anything close to the same price. Strong
Option 2: Transition to Manufacturer Programs
Telehealth companies can help patients access manufacturer patient assistance programs (PAPs), which provide free or heavily discounted brand-name GLP-1s to qualifying patients. This is a valuable service — many patients don't know these programs exist or how to apply. The limitation is that PAPs have income eligibility requirements and administrative timelines that create a gap between when a compounded program ends and when approved PAP medication arrives. Moderate
Option 3: Pivot to Different Products
Some companies have pivoted to oral GLP-1 alternatives, generic liraglutide, or other metabolic medications that are legally available. These are not equivalent substitutes in terms of weight loss efficacy, but they are legal and available. Moderate
Option 4: Exit the GLP-1 Market
Some smaller telehealth operators may simply discontinue their GLP-1 programs entirely rather than navigate the compliance and business model challenges of the transition.
The Enforcement Timeline
Regulatory changes of this magnitude rarely happen overnight, and enforcement has been uneven. Here is the honest state of the timeline:
| Milestone | Status |
|---|---|
| FDA declares semaglutide shortage resolved | Completed — 503A compounding basis eliminated for semaglutide |
| FDA declares tirzepatide shortage resolved | Completed — 503A compounding basis eliminated for tirzepatide |
| FDA enforcement actions and DOJ referrals against telehealth compounders | Ongoing — Active and escalating |
| State pharmacy board enforcement (California and others) | Ongoing — State-level restrictions updated and enforced |
| 503B bulks list exclusion for semaglutide, tirzepatide, liraglutide | Proposed — Rulemaking in process; not yet final; 503B supply continues under legal risk pending finalization |
| Full elimination of mass-market compounded GLP-1 programs | In Progress — Most major programs already shutting down or transitioning; timeline for final 503B rule varies |
The practical effect: even where the final rule is not yet in effect, the legal and business risk has become high enough that most legitimate 503B outsourcing facilities have stopped or are stopping GLP-1 compounding. Programs that continue to operate are doing so under increasing legal exposure, which creates supply stability risk for patients regardless of the formal rule finalization date. Moderate
Your Rights When a Program Ends
If your telehealth program is terminating or transitioning due to the compounding crackdown, you have rights — and they are more substantial than most patients realize.
Refund Rights for Prepaid Services
If you have prepaid for medication or a program subscription that can no longer be fulfilled as promised, you have a strong legal basis for a refund under basic contract law principles. When a party cannot perform their contractual obligations — regardless of the reason, including regulatory changes affecting the provider — they cannot retain payment for undelivered services. Strong
This applies to: prepaid quarterly or annual subscriptions, medication shipments paid for but not yet delivered, and program fees for services not yet rendered. It does not apply retroactively to medication you have already received and used.
FTC Subscription and Negative Option Protections
Federal Trade Commission regulations governing subscription and negative option programs require that cancellation be simple and that companies provide clear disclosures about what happens to prepaid amounts upon cancellation. A company that makes cancellation difficult, imposes unexpected fees, or fails to refund undelivered prepaid services may be violating FTC rules. Strong
Credit Card Chargeback Rights
If you paid by credit card and the service was not delivered as promised, you have chargeback rights under the Fair Credit Billing Act. Contact your card issuer and initiate a dispute for services not received. Time limits apply — generally 60–120 days from the statement date, though this varies by issuer. Act promptly. Strong
State Consumer Protection Laws
Every state has consumer protection statutes that prohibit unfair or deceptive trade practices. California's Consumer Legal Remedies Act and Unfair Competition Law, for example, are among the strongest in the country. If a company made representations about program availability or continuity that it knew or should have known were becoming false, state consumer protection law may provide additional remedies. Moderate
- Send a written cancellation notice to your telehealth provider (email with read receipt, or through their messaging portal) — establish a paper trail
- Request a written confirmation of cancellation and any applicable refund amount
- If they delay or refuse, initiate a credit card chargeback for undelivered future services
- If the refund is significant, consult a consumer protection attorney — many take these cases on contingency
- File a complaint with the FTC (ftc.gov/complaint) and your state attorney general if you believe you've been defrauded
Transition Options — Ranked
Here are every realistic alternative available to patients whose compounded GLP-1 program is ending, ranked from most accessible to most limited. The right option depends on your insurance status, income, and how much weight-loss efficacy you need.
Novo Nordisk (Wegovy Assist, Ozempic Savings) and Eli Lilly (Lilly Cares Foundation for Mounjaro/Zepbound) both provide their medications free of charge to qualifying patients. Income eligibility is more generous than most patients assume — household income thresholds reach into the middle-income range depending on household size. These programs are significantly underutilized. Your prescriber's office or a patient advocate can help with the application. The main limitation is the processing timeline — plan for 2–6 weeks from application to first delivery.
Apply now, before your current supply runs out — the application processing gap is the biggest practical obstacle.
Novo Nordisk's Wegovy savings card and Eli Lilly's Zepbound savings card can reduce out-of-pocket cost to $0–$25/month for eligible commercially insured patients. The critical requirement: your insurance must cover the GLP-1 medication for weight management, which requires a prior authorization. A growing number of commercial plans cover GLP-1s in 2026. Your prescriber's office initiates the prior authorization process. If approved, the savings card stacks on top of your insurance coverage to bring out-of-pocket cost to near zero.
Not available for Medicare Part D, Medicaid, or other government-funded insurance programs.
Many commercially insured patients on compounded GLP-1 programs never pursued insurance coverage because the compounded price seemed easier. With compounded options ending, it is worth formally pursuing prior authorization from your insurer. Plans that cover GLP-1s for obesity or weight management (not just diabetes) are increasingly common in 2026. If your first prior authorization request is denied, an appeal supported by your prescriber's documentation of medical necessity succeeds a significant portion of the time. This process is administratively burdensome but has no out-of-pocket cost to pursue.
Employer self-insured plans may exclude weight management drugs regardless of your insurer — check your Summary Plan Description.
Liraglutide is the active ingredient in Saxenda (weight management) and Victoza (diabetes), and generic versions are now available in the US. Generic liraglutide is an FDA-approved, commercially manufactured GLP-1 receptor agonist — not a compounded product — at a substantially lower price than semaglutide or tirzepatide. The tradeoff is efficacy: liraglutide produces approximately 5–8% average body weight loss in clinical trials, compared to 15% for semaglutide and 20–22% for tirzepatide. For patients who cannot access the higher-efficacy options, it is a legal, regulated, and clinically validated alternative. Strong
Liraglutide requires daily injection versus weekly for semaglutide and tirzepatide. The weight loss ceiling is significantly lower.
Generic semaglutide and GLP-1 biosimilars are available in Canada, Mexico, and other markets where pharmaceutical pricing regulation differs from the US. The FDA's personal importation policy does not generally permit importing prescription drugs from abroad, but enforcement against individuals importing small quantities for personal use has historically been limited. This is a legal gray area, not a clean legal option. Quality verification is a significant concern — unlike US-manufactured generics, foreign-market products are not reviewed by FDA. If you pursue this route, insist on verifiable documentation of manufacturer credentials and third-party testing. Limited
This is not a recommendation. It carries legal ambiguity and quality risks. It is listed here because patients will pursue it regardless, and informed harm reduction is better than uninformed harm.
Rybelsus is an FDA-approved oral semaglutide tablet approved for type 2 diabetes management. It is the same active molecule as Ozempic/Wegovy but in oral form. It is sometimes used off-label for weight management. The limitations are meaningful: oral absorption of semaglutide is significantly lower and more variable than injectable forms (absorption depends heavily on taking it in a specific way — fasting, with minimal water, 30 minutes before eating), and approved doses are lower than those used in STEP weight loss trials. Average weight loss with oral semaglutide is substantially less than injectable Wegovy. Moderate
Insurance coverage for Rybelsus is better in some plans than Wegovy because it has a diabetes rather than obesity indication.
What NOT to Do
Do Not Pivot to Research Peptide Sources
Research peptides are sold for laboratory use only and are not intended for human administration. The compounded GLP-1 you were receiving — even if imperfect — was manufactured by a licensed pharmacy under at least some regulatory oversight. Research peptide semaglutide from online suppliers has no manufacturing oversight, no purity guarantee, no sterility standards, and no recourse if the product harms you. The risk profile is categorically different from even a lower-quality compounding pharmacy. Strong
Do Not Accept Formulation Workarounds at Face Value
Some telehealth companies and compounding pharmacies have marketed semaglutide sodium, semaglutide acetate, or other salt-form variations as meaningfully different products that remain legal to compound. The FDA has specifically flagged this type of circumvention attempt. Before accepting a "reformulated" compounded GLP-1 as a compliant alternative, ask your prescriber or an independent pharmacist to verify the specific legal basis for continued compounding. Do not rely solely on the telehealth company's own legal characterization of their product. Strong
Do Not Wait Until Your Current Supply Runs Out
Patient assistance program applications take weeks. Prior authorization processes take weeks. If you wait until your last dose to begin the transition process, you will face a gap in treatment. GLP-1 discontinuation without a plan results in regain for most patients. Start the transition process now, before your current supply ends. Moderate
Do Not Ignore Subscription Billing After Cancellation
Some subscription services continue billing after cancellation notices, particularly during operational turmoil. Monitor your credit card statements carefully after canceling. If charges continue after a written cancellation notice, dispute them immediately with your card issuer.
Frequently Asked Questions
For most purposes, yes. The FDA has declared the national semaglutide and tirzepatide shortages resolved. Under federal law, compounding pharmacies cannot produce drugs that are "essentially a copy" of commercially available FDA-approved medications outside of an active shortage. Large-scale compounded GLP-1 programs no longer have a legal basis. Limited patient-specific compounding remains permitted under 503A rules when a prescriber documents a specific clinical need, but mass-produced copycat versions are prohibited.
If a pharmacy or telehealth company can no longer legally fulfill your subscription, you generally have a strong legal basis for a refund of prepaid amounts for services not yet delivered. Contact your provider in writing to request cancellation and a refund of prepaid balances. If you paid by credit card, you have chargeback rights for services not received. Document all communications and act promptly — chargeback time limits apply.
503B outsourcing facilities are large-scale, FDA-registered compounding operations that can manufacture drugs in bulk without individual patient prescriptions. The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the bulk drug substances list that 503B facilities may use. Once this rule takes effect, mass-scale GLP-1 compounding by 503B facilities — which supply most major telehealth programs — becomes illegal. The rule is proposed but not yet final; however, most facilities are already stopping GLP-1 compounding in anticipation.
These companies can still offer GLP-1 programs — but not using compounded medications. Their options are prescribing brand-name medications, facilitating access to manufacturer savings programs, or pivoting to different products. Brand-name pricing makes it very difficult to serve patients who chose compounded programs because of cost. How individual companies navigate this transition varies — check your specific provider's current terms directly.
In limited circumstances, yes. A licensed 503A compounding pharmacy can still prepare a customized GLP-1 formulation if your prescriber documents a specific, individualized medical need — such as a documented allergy to an inactive ingredient in the commercial formulation. General desire for a lower-cost alternative is not sufficient medical justification. Many pharmacies are declining to compound GLP-1s at all given the compliance risk.
Novo Nordisk (Wegovy Assist, Ozempic PAP) and Eli Lilly (Lilly Cares Foundation for Mounjaro/Zepbound) both provide their medications free or at very low cost to patients who meet income and insurance criteria. Income thresholds are relatively generous — many patients who assumed they wouldn't qualify actually do. These are among the most underutilized resources in the GLP-1 space and should be the first option to explore before paying out of pocket for brand-name medications.
Yes, for commercially insured patients. Manufacturer savings cards can reduce the out-of-pocket cost of brand-name GLP-1s to $0–$25/month for patients with qualifying commercial insurance. The critical limitation: these cards are not available to Medicare or Medicaid patients. If you have commercial insurance that covers GLP-1s for weight management, a savings card can essentially eliminate out-of-pocket cost — but the insurance must first approve coverage via prior authorization.
Yes — generic liraglutide is the most accessible lower-cost FDA-approved GLP-1 option. It is the active ingredient in Victoza (diabetes) and Saxenda (weight loss), and generics are now available. The tradeoff is efficacy: liraglutide produces approximately 5–8% average body weight loss versus 15–22% for semaglutide and tirzepatide. For patients who cannot access the higher-efficacy options through insurance or patient assistance, it is a legal, regulated alternative. Oral semaglutide (Rybelsus) is another FDA-approved option sometimes used off-label for weight management, though its absorption is less predictable.